Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308605 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6TSHRMME | |
| SCHEMBL308774 | 0.87 | FOLH1 (0.54) | CYP1A2CYP3A4CYP2D6TSHRMME | |
| SCHEMBL308775 | 0.87 | FOLH1 (0.54) | CYP1A2CYP3A4CYP2D6TSHRMME | |
| SCHEMBL28154840 | 0.86 | CA2 (0.47) | CYP1A2CYP3A4CYP2D6TSHRMME | |
| SCHEMBL17491827 | 0.86 | CA2 (0.47) | CYP1A2CYP3A4CYP2D6TSHRMME | |
| SCHEMBL6323122 | 0.86 | ATM (0.56) | CYP1A2CYP3A4CYP2D6TSHRL3MBTL1 | |
| SCHEMBL7763338 | 0.84 | LMNA (0.49) | CYP1A2CYP3A4CYP2D6TSHRMME | |
| SCHEMBL27676146 | 0.83 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL15421626 | 0.81 | ITGA4 (0.61) | CYP1A2CYP3A4CYP2D6TSHRNPSR1 | |
| SCHEMBL15421627 | 0.81 | ITGA4 (0.61) | CYP1A2CYP3A4CYP2D6TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102224238-B | Non-natural amino acid replication-dependent microorganisms and vaccines | AMBRX INC | 2015-06-10 | — | — | CN | claimed |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | ELANCO US INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12247058-B2 | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-11 | — | — | US | disclosed |
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| CN-110637027-B | Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof | 百时美施贵宝公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4398915-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1 TALEN KNOCKDOWN | Iovance Biotherapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240189392-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2024-06-13 | — | — | US | disclosed |
| US-11993637-B2 | Modified FGF-21 polypeptides with non-naturally encoded amino acids | AMBRX, INC. | 2024-05-28 | — | — | US | disclosed |
| CN-110078814-B | Modified FGF-21 polypeptides and uses thereof | 百时美施贵宝公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2024055017-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1/TIGIT TALEN DOUBLE KNOCKDOWN | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-1914223-A | Modified human four-helix bundle polypeptides and uses thereof | AMBRX INC (US) | 2007-02-14 | — | — | CN | disclosed |
| US-20060217532-A1 | Incorporating a non-natural amino acid having oxime, carbonyl, dicarbonyl, and/or hydroxylamine group into a terminal or internal position within a polypeptide | AMBRX, INC. (US) | 2006-09-28 | — | — | US | disclosed |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | AMBRX, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | AMBRX, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| EP-1636340-A2 | UNNATURAL REACTIVE AMINO ACID GENETIC CODE ADDITIONS | The Scripps Research Institute (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | AMBRX, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| EP-1613735-A2 | EXPANDING THE EUKARYOTIC GENETIC CODE | The Scripps Research Institute (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | AMBRX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005003294-A2 | UNNATURAL REACTIVE AMINO ACID GENETIC CODE ADDITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004094593-A2 | EXPANDING THE EUKARYOTIC GENETIC CODE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | CYP1A2 4108/4885CYP3A4 4643/4885CYP2D6 3899/4885 |
| US-11993637-B2 | Modified FGF-21 polypeptides with non-naturally encoded amino acids | FGF1, FGF2, FGF23 | CYP1A2 4780/4885CYP3A4 4879/4885CYP2D6 4807/4885 |
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | IFNG, IFNAR1, EIF2AK2 | CYP1A2 4469/4885CYP3A4 3838/4885CYP2D6 3408/4885 |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | CD2BP2, CD74, LGALS3BP | CYP1A2 4885/4885CYP3A4 4880/4885CYP2D6 4863/4885 |
| US-20060189529-A1 | Linked to polyoxyethylene glycol via oximination; improved half-life | GHRHR, VEGFA, SHBG | CYP1A2 1782/4885CYP3A4 2772/4885CYP2D6 2812/4885 |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | NPEPPS, COASY, BCAT1 | CYP1A2 2977/4885CYP3A4 3178/4885CYP2D6 1819/4885 |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | AARS1, NPEPPS, GLUL | CYP1A2 4851/4885CYP3A4 4671/4885CYP2D6 4299/4885 |
| US-20060217532-A1 | Incorporating a non-natural amino acid having oxime, carbonyl, dicarbonyl, and/or hydroxylamine group into a terminal or internal position within a polypeptide | DAO, DNPEP, PTMS | CYP1A2 3971/4885CYP3A4 3467/4885CYP2D6 2468/4885 |
| US-12247058-B2 | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof | FGF1, FGF2, FGF23 | CYP1A2 4830/4885CYP3A4 4882/4885CYP2D6 4855/4885 |
| US-20240189392-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP3 | CYP1A2 4800/4885CYP3A4 4860/4885CYP2D6 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.